Biosimilar switch works for most patients in Real-World study
NCT ID NCT02998398
First seen Jan 16, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This study tested what happens when patients with rheumatoid arthritis, Crohn's disease, or eye inflammation switch from the original drug Remicade to its lower-cost biosimilar Inflectra. Over 260 adults who had been on Remicade for at least 4 months were switched. The main goal was to see how many stayed on Inflectra after three doses. Results help doctors understand if switching is a safe and effective option in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Cochin
Paris, Paris, 75014, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
biosimilar infliximab (Inflectra)
What this could lead to
If successful, this could show that switching to a biosimilar is safe and effective, potentially lowering treatment costs for patients with inflammatory diseases.
What could go wrong
This is a small, single-hospital study without a comparison group. Results may not apply to all patients, and some may experience disease flares or develop antibodies after switching.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.